Welcome to our dedicated page for Monopar Therapeutics news (Ticker: MNPR), a resource for investors and traders seeking the latest updates and insights on Monopar Therapeutics stock.
Monopar Therapeutics Inc. (MNPR) is a clinical-stage biopharmaceutical company whose news flow centers on drug development milestones, scientific data presentations, financial updates, and capital markets activity. Public communications describe a focus on late-stage ALXN1840 for Wilson disease and MNPR-101-based radiopharmaceutical programs for imaging and treating advanced cancers.
News items for Monopar commonly include clinical and scientific results, such as data from the ALXN1840-WD-204 copper balance study and pooled long-term neurological and safety analyses in Wilson disease. The company also reports on presentations at major medical meetings, including the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting and the American Neurological Association (ANA) Annual Meeting, as well as publications in peer-reviewed journals like the Journal of Hepatology.
Investors and observers can also find updates on radiopharmaceutical programs, including progress in Phase 1 imaging and therapeutic trials with MNPR-101-Zr and MNPR-101-Lu, and regulatory developments such as U.S. Food and Drug Administration authorization for an Expanded Access Program in advanced solid tumors. In addition, Monopar issues press releases on financial results, describing quarterly performance, research and development spending, and general and administrative expenses, alongside information on cash resources and capital-raising transactions.
Further topics in Monopar’s news include capital markets events, such as underwritten offerings of common stock and pre-funded warrants, share repurchase agreements with existing stockholders, and inclusion in the Russell 3000 and Russell 2000 indexes. Readers interested in MNPR news can use this page to follow these developments and review how the company describes the evolution of its Wilson disease and radiopharmaceutical programs over time.
Monopar Therapeutics (Nasdaq: MNPR) has announced the pricing of a public offering of common stock at $16.25 per share, aiming to raise approximately $19.2 million in gross proceeds. The offering, expected to close on October 30, 2024, features participation from notable investors including Janus Henderson Investors and RA Capital Management. Rodman & Renshaw serves as the exclusive placement agent. The company plans to use the proceeds for general corporate purposes, including research and development, clinical trials, product manufacturing, and working capital.
Monopar Therapeutics (Nasdaq: MNPR) announced plans for a best efforts public offering of common stock. The clinical-stage biotech company intends to use the proceeds for general corporate purposes, including research and development, clinical trials, product manufacturing, and working capital. Rodman & Renshaw is serving as the exclusive placement agent. The offering will be conducted under a previously filed S-3 registration statement. The final terms will be disclosed in a prospectus supplement to be filed with the SEC.
Monopar Therapeutics (Nasdaq: MNPR) has secured an exclusive worldwide license from Alexion, AstraZeneca Rare Disease for ALXN-1840, a Wilson disease drug candidate that completed Phase 3 trials meeting its primary endpoint. The agreement involves an upfront payment combining cash and Monopar equity, plus future tiered royalties and milestone payments. Monopar will oversee all future global development and commercialization. This acquisition follows Alexion's 2023 termination of the ALXN-1840 program after reviewing Phase II mechanistic trials and regulatory discussions.
Monopar Therapeutics Inc. (Nasdaq: MNPR) is presenting encouraging data from its uPAR radiopharmaceutical program at the EANM 2024 Annual Congress. The presentation, recognized as a "Top-Rated Oral Presentation," showcases favorable human clinical dosimetry data for MNPR-101-Lu, derived from MNPR-101-Zr imaging studies.
Key highlights include:
- Favorable organ safety profile at high Lu-177 therapeutic dose levels
- Promising uPAR targeting in solid tumors
- Encouraging tumor uptake and low off-target binding
- Estimated favorable radiation dosimetry safety profile for off-target effects
The company's Phase 1a trial for MNPR-101-Lu (NCT06617169) and Phase 1 imaging and dosimetry trial for MNPR-101-Zr (NCT06337084) are ongoing.
Monopar Therapeutics Inc. (Nasdaq: MNPR) has filed a provisional patent for new therapeutic radiopharmaceuticals based on a family of linkers connecting radioisotopes with targeting agents, including Monopar's uPAR targeting antibody MNPR-101. The patent filing covers:
- Composition of Matter: Claims for a family of linkers and Monopar's uPAR targeting agents linked with these and therapeutic radioisotopes
- Stability and Biodistribution: Proprietary new linkers designed to enhance stability and biodistribution of Monopar's therapeutic radiopharmaceuticals
- Versatility: The new linker family works with various isotopes and targeting molecules, including small molecules/peptides and antibodies
The company believes these linkers could create new proprietary radiopharmaceuticals targeting high-value cancer targets and potentially lead to licensing and development collaborations in the industry.
Monopar Therapeutics Inc. (Nasdaq: MNPR) has initiated a Phase 1a clinical trial for its novel therapeutic radiopharmaceutical MNPR-101-Lu in patients with advanced cancers. The open-label dose-escalation study will recruit patients with solid tumors, focusing on those participating in the ongoing MNPR-101-Zr Phase 1 imaging and dosimetry trial. The first clinical site activated is the Melbourne Theranostic Innovation Centre (MTIC) in Australia.
MNPR-101 is Monopar's proprietary antibody targeting the urokinase plasminogen activator receptor (uPAR), expressed in various tumor types. The company aims to deliver targeted radiopharma therapy that kills cancer cells while minimizing damage to healthy tissue. Recent clinical and preclinical data have shown highly specific and durable tumor uptake of MNPR-101-Zr.
This trial may be the world's first uPAR-targeted therapeutic radiopharma clinical trial, with the goal of identifying tumors using MNPR-101-Zr and treating them with MNPR-101-Lu.
Monopar Therapeutics Inc. (Nasdaq: MNPR) announced positive early data from its ongoing MNPR-101-Zr Phase 1 imaging and dosimetry clinical trial, validating the tumor targeting ability of MNPR-101-Zr in humans. The trial focuses on MNPR-101, a proprietary first-in-class humanized monoclonal antibody targeting cancers expressing the urokinase plasminogen activator receptor (uPAR).
Key findings include:
- Highly preferential uptake of MNPR-101-Zr in metastatic tumors relative to normal tissue
- Specificity and durability of MNPR-101-Zr in tumor targeting
- Alignment of MNPR-101-Zr uptake with previously observed metastatic tumors on FDG PET imaging
Monopar also received clearance in Australia to initiate an MNPR-101-Lu Phase 1 therapeutic clinical trial, scheduled for Q4 2024. Additional data will be presented at the European Association of Nuclear Medicine 2024 Annual Congress in October.
Monopar Therapeutics (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative cancer treatments, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. Chandler D. Robinson, MD, Monopar's CEO, will present at the conference. Key details include:
- Presentation will be webcast starting Monday, September 9, 2024 at 7:00 a.m. ET
- In-person one-on-one meetings will be held at the Lotte New York Palace, NY
- Conference dates: September 9 - 11, 2024
This event provides Monopar an opportunity to showcase its progress and connect with potential investors, potentially impacting its stock performance (MNPR).
Monopar Therapeutics (Nasdaq: MNPR), a clinical-stage radiopharma company, has regained compliance with Nasdaq's minimum bid price requirement. The company received notice from Nasdaq that it has met the listing rule 5550(a)(2), which requires a minimum bid price of $1.00 per share for at least 10 consecutive trading sessions. This development ensures Monopar's continued listing on the Nasdaq stock exchange, maintaining its visibility and access to capital markets. The compliance status is important for the company's ongoing efforts in developing innovative cancer treatments.
Monopar Therapeutics Inc. (Nasdaq: MNPR) has received Human Research Ethics Committee (HREC) clearance in Australia to begin a Phase 1 therapeutic trial of its novel radiopharmaceutical MNPR-101-Lu. This treatment combines lutetium-177 with Monopar's proprietary humanized monoclonal antibody MNPR-101, which targets the urokinase plasminogen activator receptor (uPAR). The trial will enroll patients with advanced solid cancers and follows the ongoing MNPR-101-Zr imaging and dosimetry clinical trial.
Preclinical studies have shown promising results, with MNPR-101-Lu demonstrating durable antitumor effects in a human pancreatic cancer xenograft mouse model. The treatment achieved complete tumor elimination after a single injection, lasting throughout the 90-day study. Imaging data also revealed high specificity and durable uptake of MNPR-101-Lu in tumors relative to normal tissue.